<DOC>
	<DOC>NCT01127503</DOC>
	<brief_summary>This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with velocardiofacial syndrome (VCFS).</brief_summary>
	<brief_title>Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Facial Paralysis</mesh_term>
	<mesh_term>alpha-Methyltyrosine</mesh_term>
	<criteria>Key 1. Females of childbearing potential cannot be at risk of pregnancy during the study. 2. Genetically confirmed diagnosis of VCFS at the time of screening. 3. Must have one of the following Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSMIV TR) diagnoses (applicable based upon clinical assessments): schizophrenia, schizoaffective disorder, psychosis not otherwise specified (NOS), bipolar disorder, or mood disorder with psychotic features. 4. A total PANSS composite score &gt;65. 5. Willing to discontinue psychotropic medications. Key 1. Evidence of acute suicidality. 2. Known or observed clinically significant cardiovascular, pulmonary, renal, hepatic, or gastrointestinal disorders; other clinically significant psychiatric/neurological and sleep disorders by DSMIVTR criteria; endocrine, or hematological or metabolic diseases. 3. Full scale IQ of less than 50. 4. Pregnancy. 5. Not using a reliable means of contraception. 6. Systolic blood pressure of ≤110 mm/Hg or ≥160 mm/Hg, diastolic blood pressure ≤60 mm/Hg or ≥90 mm/Hg, or has clinically symptomatic orthostatic changes. 7. QTcF &gt; 450 msec, or PR &gt; 250 msec, or QRS &gt; 110 msec on ECG. 8. History of seizure disorder.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Patients with velocardiofacial syndrome and psychosis</keyword>
</DOC>